Avalide: Dual-Action Blood Pressure Control for Lasting Cardiovascular Health
| Product dosage: 162.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.89 | $56.76 (0%) | 🛒 Add to cart |
| 60 | $1.43 | $113.52 $86.00 (24%) | 🛒 Add to cart |
| 90 | $1.27 | $170.28 $114.38 (33%) | 🛒 Add to cart |
| 120 | $1.19 | $227.04 $142.76 (37%) | 🛒 Add to cart |
| 180 | $1.11 | $340.56 $200.38 (41%) | 🛒 Add to cart |
| 270 | $1.06
Best per pill | $510.84 $286.38 (44%) | 🛒 Add to cart |
Synonyms | |||
Avalide combines two proven antihypertensive agents—irbesartan and hydrochlorothiazide—into a single, convenient tablet designed for comprehensive blood pressure management. This fixed-dose combination therapy targets multiple pathways of hypertension through angiotensin II receptor blockade and diuretic action, offering synergistic efficacy with simplified dosing. Clinically validated for patients requiring more than one agent to achieve target blood pressure, it provides a rational therapeutic option that supports adherence while reducing pill burden. Its well-established safety profile and predictable pharmacokinetics make it a cornerstone therapy in modern hypertension management protocols.
Features
- Contains irbesartan (an ARB) and hydrochlorothiazide (a thiazide diuretic) in fixed-dose combinations
- Available in strengths: 150 mg/12.5 mg, 300 mg/12.5 mg, and 300 mg/25 mg
- Once-daily oral administration
- Bioavailability unaffected by food intake
- Peak plasma concentrations reached within 1.5–2 hours for irbesartan and 1–2.5 hours for hydrochlorothiazide
- Mean elimination half-life of 11–15 hours for irbesartan and 6–15 hours for hydrochlorothiazide
- Hepatic metabolism via CYP2C9 with primarily biliary/fecal excretion
- Manufactured under current Good Manufacturing Practices (cGMP) standards
Benefits
- Provides dual-mechanism blood pressure reduction through RAAS inhibition and volume control
- Demonstrates additive antihypertensive effect greater than either component alone
- Supports consistent 24-hour blood pressure control with once-daily dosing
- Reduces cardiovascular risk through effective hypertension management
- Minimizes pill burden and simplifies treatment regimens
- Offers flexible dosing options to accommodate individual patient needs
Common use
Avalide is indicated for the treatment of hypertension, particularly in patients for whom combination therapy is appropriate. It is commonly prescribed when monotherapy provides insufficient blood pressure control or when clinical assessment suggests benefit from targeting multiple physiological pathways. The medication is often utilized as part of comprehensive cardiovascular risk reduction strategies, especially in patients with additional risk factors such as age, family history, or comorbid conditions. Clinical practice guidelines support its use as both initial combination therapy in select high-risk patients and as step-up therapy when monotherapy proves inadequate.
Dosage and direction
The recommended starting dose is one Avalide 150 mg/12.5 mg tablet once daily. dosage may be titrated to Avalide 300 mg/12.5 mg after 2–4 weeks based on blood pressure response. For patients requiring additional blood pressure reduction, the dose may be increased to Avalide 300 mg/25 mg. The maximum recommended daily dose is 300 mg/25 mg. Administration should occur at approximately the same time each day, with or without food. Tablets should be swallowed whole with a glass of water; they should not be split, crushed, or chewed. Dose adjustment may be necessary in elderly patients or those with renal impairment.
Precautions
Periodic assessment of renal function is recommended, particularly in patients with pre-existing renal impairment. Serum electrolyte levels (especially potassium, sodium, and magnesium) should be monitored regularly, especially during initiation and after dosage adjustments. Use with caution in patients with impaired hepatic function or history of liver disease. May cause dizziness or drowsiness; patients should exercise caution when operating machinery or driving until their response to therapy is established. Adequate hydration should be maintained, especially during hot weather or vigorous exercise. Photosensitivity reactions may occur; appropriate sun protection is advised.
Contraindications
Avalide is contraindicated in patients with known hypersensitivity to irbesartan, hydrochlorothiazide, or any component of the formulation. Do not use in patients with anuria or severe renal impairment (CrCl <30 mL/min). Contraindicated in patients with refractory hypokalemia, hypercalcemia, or symptomatic hyperuricemia. Not recommended during pregnancy, particularly second and third trimesters, due to potential fetal harm. Should not be used concomitantly with aliskiren in patients with diabetes or renal impairment (CrCl <60 mL/min).
Possible side effects
Common adverse reactions (≥2%) include dizziness, fatigue, musculoskeletal pain, nausea, and hyperkalemia. Less frequently reported effects include orthostatic hypotension, increased blood creatinine, headache, diarrhea, and upper respiratory infection. Rare but serious side effects may include angioedema, acute renal failure, severe hypotension, electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia), and pancreatitis. Dermatological reactions including photosensitivity and rash have been reported. Laboratory abnormalities may include increased BUN, creatinine, and liver enzymes.
Drug interaction
Concomitant use with other RAAS inhibitors may increase risk of hypotension, hyperkalemia, and renal impairment. NSAIDs may reduce antihypertensive effect and increase risk of renal impairment. Lithium levels may increase with concurrent use. Potassium-sparing diuretics or potassium supplements may lead to hyperkalemia. Enhanced hypotensive effect may occur with other antihypertensives or alcohol. Thiazides may increase toxicity of digitalis glycosides. Corticosteroids and ACTH may enhance electrolyte depletion. Cholestyramine and colestipol may reduce absorption of hydrochlorothiazide.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is near the time for the next dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed dose. Patients should be advised to maintain a consistent dosing routine and consider using reminder systems if missed doses occur frequently.
Overdose
Symptoms of overdose may include hypotension, tachycardia, bradycardia, dizziness, decreased urinary output, and electrolyte disturbances. Laboratory findings may show hypokalemia, hyponatremia, and hypochloremic alkalosis. Management involves supportive care with close monitoring of vital signs and electrolyte balance. Gastric lavage may be considered if ingestion was recent. IV normal saline may be administered for hypotension, with careful attention to fluid status. Hemodialysis is not effective for irbesartan removal but may help correct electrolyte abnormalities.
Storage
Store at controlled room temperature 20°–25°C (68°–77°F) with excursions permitted between 15°–30°C (59°–86°F). Keep container tightly closed and protect from moisture and light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly dispose of any unused medication according to local regulations.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual patient needs may vary, and healthcare professionals should exercise clinical judgment when prescribing Avalide. Patients should consult their healthcare provider for personalized medical advice and report any adverse reactions. Full prescribing information including boxed warnings should be reviewed before initiation of therapy.
Reviews
Clinical studies demonstrate that Avalide provides significant blood pressure reduction compared to monotherapy components, with approximately 70–80% of patients achieving target blood pressure goals. Long-term extension studies show maintained efficacy over 12–24 months of treatment. Real-world evidence supports improved adherence rates compared to free combination therapy. Healthcare providers report satisfaction with its efficacy profile and patient tolerance. Some studies note particular benefit in elderly hypertensive patients and those with isolated systolic hypertension.